These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 32696072)

  • 1. Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides.
    Fujiki F; Tsuboi A; Morimoto S; Hashimoto N; Inatome M; Nakajima H; Nakata J; Nishida S; Hasegawa K; Hosen N; Oka Y; Oji Y; Sogo S; Sugiyama H
    Cancer Immunol Immunother; 2021 Jan; 70(1):253-263. PubMed ID: 32696072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.
    Lin Y; Fujiki F; Katsuhara A; Oka Y; Tsuboi A; Aoyama N; Tanii S; Nakajima H; Tatsumi N; Morimoto S; Tamanaka T; Tachino S; Hosen N; Nishida S; Oji Y; Kumanogoh A; Sugiyama H
    J Immunother; 2013 Apr; 36(3):159-70. PubMed ID: 23502763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of mouse helper epitopes for WT1-specific CD4
    Nakajima H; Nakata J; Imafuku K; Hayashibara H; Isokawa K; Udaka K; Fujiki F; Morimoto S; Hasegawa K; Hosen N; Hashii Y; Nishida S; Tsuboi A; Oka Y; Oji Y; Sogo S; Sugiyama H
    Cancer Immunol Immunother; 2021 Nov; 70(11):3323-3335. PubMed ID: 34272593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining MHC class II T helper epitopes for WT1 tumor antigen.
    Kobayashi H; Nagato T; Aoki N; Sato K; Kimura S; Tateno M; Celis E
    Cancer Immunol Immunother; 2006 Jul; 55(7):850-60. PubMed ID: 16220325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
    J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors.
    Suginobe N; Nakamura M; Takanashi Y; Ban H; Gotoh M
    Clin Transl Oncol; 2023 Feb; 25(2):396-407. PubMed ID: 36138335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
    Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
    Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients.
    Ochsenreither S; Fusi A; Geikowski A; Stather D; Busse A; Stroux A; Letsch A; Keilholz U
    Cancer Immunol Immunother; 2012 Mar; 61(3):313-22. PubMed ID: 21898091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.
    Nakae Y; Oka Y; Fujiki F; Morimoto S; Kamiya T; Takashima S; Nakata J; Nishida S; Nakajima H; Hosen N; Tsuboi A; Kyo T; Oji Y; Mizuguchi K; Kumanogoh A; Sugiyama H
    Cancer Immunol Immunother; 2015 Jul; 64(7):791-804. PubMed ID: 25835542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular and Humoral Immune Responses Induced by an HLA Class I-restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer.
    Nishida S; Morimoto S; Oji Y; Morita S; Shirakata T; Enomoto T; Tsuboi A; Ueda Y; Yoshino K; Shouq A; Kanegae M; Ohno S; Fujiki F; Nakajima H; Nakae Y; Nakata J; Hosen N; Kumanogoh A; Oka Y; Kimura T; Sugiyama H
    J Immunother; 2022 Jan; 45(1):56-66. PubMed ID: 34874330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers.
    Oka Y; Tsuboi A; Elisseeva OA; Nakajima H; Fujiki F; Kawakami M; Shirakata T; Nishida S; Hosen N; Oji Y; Kawase I; Sugiyama H
    ScientificWorldJournal; 2007 May; 7():649-65. PubMed ID: 17619750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decade-long WT1-specific CTLs induced by WT1 peptide vaccination.
    Suwabe T; Shibasaki Y; Tamura S; Katagiri T; Fuse K; Ida-Kurasaki T; Ushiki T; Sone H; Narita M; Masuko M
    Int J Hematol; 2024 Apr; 119(4):399-406. PubMed ID: 38427208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance.
    Chaise C; Buchan SL; Rice J; Marquet J; Rouard H; Kuentz M; Vittes GE; Molinier-Frenkel V; Farcet JP; Stauss HJ; Delfau-Larue MH; Stevenson FK
    Blood; 2008 Oct; 112(7):2956-64. PubMed ID: 18502835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
    Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
    J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
    Oji Y; Hashimoto N; Tsuboi A; Murakami Y; Iwai M; Kagawa N; Chiba Y; Izumoto S; Elisseeva O; Ichinohasama R; Sakamoto J; Morita S; Nakajima H; Takashima S; Nakae Y; Nakata J; Kawakami M; Nishida S; Hosen N; Fujiki F; Morimoto S; Adachi M; Iwamoto M; Oka Y; Yoshimine T; Sugiyama H
    Int J Cancer; 2016 Sep; 139(6):1391-401. PubMed ID: 27170523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination.
    Fujiki F; Oka Y; Kawakatsu M; Tsuboi A; Tanaka-Harada Y; Hosen N; Nishida S; Shirakata T; Nakajima H; Tatsumi N; Hashimoto N; Taguchi T; Ueda S; Nonomura N; Takeda Y; Ito T; Myoui A; Izumoto S; Maruno M; Yoshimine T; Noguchi S; Okuyama A; Kawase I; Oji Y; Sugiyama H
    Anticancer Res; 2010 Jun; 30(6):2247-54. PubMed ID: 20651376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.
    Nakajima H; Oka Y; Tsuboi A; Tatsumi N; Yamamoto Y; Fujiki F; Li Z; Murao A; Morimoto S; Hosen N; Shirakata T; Nishida S; Kawase I; Isaka Y; Oji Y; Sugiyama H
    Vaccine; 2012 Jan; 30(4):722-9. PubMed ID: 22133512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides.
    Nakata J; Nakajima H; Hayashibara H; Imafuku K; Morimoto S; Fujiki F; Motooka D; Okuzaki D; Hasegawa K; Hosen N; Tsuboi A; Oka Y; Kumanogoh A; Oji Y; Sugiyama H
    Oncotarget; 2018 Nov; 9(89):36029-36038. PubMed ID: 30542516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cancer antigen WT1-targeting treatment for the malignancies].
    Oka Y; Kawase I
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):375-82. PubMed ID: 18974621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.